Department of Periodontics, K.V.G. College & Hospital,
Kurunjibhag, Sullia (d.k.), Karnataka, 574327, India
NCT Number: NCT02390687
Periodontitis is an infectious inflammatory disease. Bacteria modulate the inflammatory response and alter the diversity of periodontal disease. In recent years, various host-response modulation therapies have been developed to block the pathways responsible for periodontal tissue breakdown.
There have been significant changes with respect to the effectiveness of, and attitudes towards conventional antimicrobial therapy to combat disease. With the threat of widespread antibiotic resistance rendering many antibiotics useless against important diseases, there is an increased necessity not only to minimise antibiotic use and develop novel non-antibiotic-based treatments, but also to raise the profile of disease prevention. One approach that has gained interest over recent years is the use of probiotic bacteria for oral applications. The rationale for their use in oral health care stems from the increase in evidence that supports their claims for benefit for a range of diseases. Lactobacilli play an important role in the maintenance of health by stimulating the natural immunity as well as by contributing to the balance of the microflora, by interacting with the other members of the flora. The application of health promoting bacteria for therapeutic purposes, is one of the strongest emerging fields. Time has come to shift the paradigm of the treatment from specific bacteria elimination to alteration of the bacterial ecology by using probiotics.
So the purpose of this study is to discover a more promising approach for the treatment of chronic periodontitis .
Looking for future studies?
Notify Me35 year–49 year
All sexes
Interventional
Phase 3
Kurunjibhag, Sullia (d.k.), Karnataka, 574327, India
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Each probiotic lozenge contains not less than 1 billion colony forming unit of Lactobacillus brevis CD2
Other names: L. brevis CD2 Lozenges
Each placebo lozenge contains all excipients except the active constituent (Lactobacillus brevis CD2)
Time frame: 8 weeks
Improvement in periodontal clinical indices, namely, Gingival Index (GI), Bleeding on probing (BOP), Probing Pocket Depth (PPD) and Clinical attachment Loss (CAL).
Time frame: 8 weeks
Assessment of changes in bone patterns in bith group using digital radio-graphic technique
Next Gen Pharma India Pvt. Ltd.
Industry
Evaluation of the Efficacy of Probiotics in Chronic Periodontitis Patients-A Randomized Placebo Controlled Study.
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06893107
Chronic Disease, Chronic Periodontitis
Fujairah, Emirate of Fujairah, United Arab Emirates
View Trial DetailsNCT04274244
Alveolar Bone Loss, Bone Diseases
Valencia, Spain
View Trial DetailsNCT07671456
Aggressive Periodontitis, Chronic Disease
View Trial DetailsNCT03863249
Alveolar Bone Loss, Bone Diseases
Valencia, Spain
View Trial Details